Bloomberg Stock Movers
2026-10-13 · Hosted by — · Bloomberg / iHeartMedia
Executive Summary
Bank earnings season kicked off with JPMorgan and Wells Fargo both missing on key revenue lines even as profits held up. JPMorgan's fixed income, currencies, and commodities (FICC) trading revenue of $5.37 billion fell well below the $6 billion estimate and marked the unit's first year-over-year decline in over two years, setting what hosts called "a low bar" for other banks reporting this week. Wells Fargo's total revenue of $21.9 billion also missed estimates, though the bank trimmed costs with an 8% headcount cut.
Key Stories & Changes
1. JPMorgan Earnings: Trading Revenue Miss
JPM: JPMorgan — Revenue in line to slightly below — FICC trading revenue missed badly, first YoY decline in 2+ years
Total revenue: $50.9 billion, slightly below estimates
FICC (fixed income, currencies, commodities) trading revenue: $5.37 billion, well below the $6 billion estimate — first year-over-year decline for the business in over two years
Investment banking revenue: $3.1 billion, a miss
Equity sales and trading: nearly $5 billion, came in stronger than estimates
Net interest income: $27.2 billion, stronger than estimates
Hosts noted the FICC miss sets "a low bar" for other bulge-bracket banks still to report this week
2. Wells Fargo Earnings: Revenue Miss, Cost Cuts
WFC: Wells Fargo — -1.4% — Total revenue missed despite cost discipline
Net interest income: ~$12.5 billion, matching estimates; guided to ~$13 billion for Q4
Total revenue: $21.9 billion, below estimates
Non-interest expenses: fell 1%, aided by an 8% headcount cut and lower-than-expected severance costs
3. UnitedHealth Group Raises Guidance
UNH: UnitedHealth Group — +2.2% — Raised full-year profit outlook on easing medical costs
Raised full-year EPS guidance to at least $20.50, up 50 cents from prior guidance
Q3 top- and bottom-line results beat estimates
Medical loss ratio: 88 cents spent on claims per dollar of premium collected, better (lower) than expected
Benefited from $610 million in favorable reserve releases — money set aside for claims that ultimately weren't needed
4. Johnson & Johnson Falls Despite Beat
JNJ: Johnson & Johnson — -3% — Beat estimates but stock fell after a 27% pre-earnings run-up
Stock had risen 27% year-to-date heading into the print, setting a high bar
Raised profit guidance on strong demand for newer cancer and autoimmune disease drugs
Offset by anemic growth in the medical device business; CFO said the company is leaning toward an orthopedic unit spinoff rather than a sale
Q3 top line matched estimates; adjusted EPS came in above estimates despite the stock's negative reaction
Trends Identified
1. Bank Trading Revenue Momentum Cooling
JPMorgan's first FICC trading revenue decline in over two years, paired with a soft investment banking print, suggests the multi-quarter capital markets boom that had buoyed bank earnings may be losing steam just as the broader market looks to banks for Q3 earnings confirmation.
2. Healthcare Earnings Diverge on Cost Management, Not Top-Line Growth
UnitedHealth's beat was driven primarily by medical cost containment (lower claims ratios and reserve releases) rather than revenue strength, while J&J's sell-the-beat reaction shows investors are scrutinizing segment-level growth (medical devices) even when headline numbers beat, especially after a strong pre-earnings rally. ---
Sentiment Analysis
Overall Market Sentiment: Mixed
Bank results came in softer than hoped on trading revenue, while healthcare names showed a split between cost-driven beats (UnitedHealth) and growth-quality concerns despite beats (J&J).
Risk Factors Highlighted
Bank trading revenue deceleration: JPMorgan's FICC trading revenue miss and first year-over-year decline in two years could signal a broader slowdown for peer banks reporting later this week.
Investment banking softness: JPMorgan's investment banking revenue missed estimates, suggesting deal activity headwinds persist.
Medical device segment weakness: J&J's device business growth remains weak, prompting a potential orthopedic unit spinoff.
High bar from pre-earnings rallies: J&J's 27% YTD run-up into earnings left little room for anything short of a clean beat across all segments.
This episode was covered in today's [The Market Signal — 2026-10-13](https://marketsignal.beehiiv.com/p/the-market-signal-2026-10-13), a cross-source synthesis of multiple podcast reports.